FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

\A/aabiaataa	D C	20540	
Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box if no longer subject to

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Se	ee Instruction 1	0.																		
Name and Address of Reporting Person* Hayes Christopher G.						2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
nayes	CHIIStoph	lei G.										,			Direc			10% Ov		
(1 aat)	/F:-	nat) (A	المامالم)		<u> </u>									V	Office below	er (give title /)		Other (s	specify	
(Last) (First) (Middle) C/O VERRICA PHARMACEUTICALS INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/26/2024									CHIEF LEGAL OFFICER						
44 WEST GAY STREET, SUITE 400																				
44 WEST GAT STREET, SOTTE 400					L															
(Street)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)					
WEST	PA	1	9380											v	Form	filed by One	e Rep	orting Perso	on	
CHESTE	ER	•	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,												Form filed by More than One Reportir Person				orting	
(City)	(Sta	ate) (Z	Zip)																	
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	Bene	ficial	ly Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			4 and Secur Benef		ities For icially (D) d Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
										v	Amount	(A) (D)	P P	rice	Transa	ction(s) 3 and 4)			(111501.4)	
Common Stock 08/26/2					.024			S ⁽¹⁾		26,183	D	\$	2.66(2	6 ⁽²⁾ 115,303			D			
Common Stock 08/27/2					2024			S ⁽¹⁾		9,530	D	\$	2.46 ⁽³	6(3) 105,773			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, if any			4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rities ired osed	6. Date Expirat (Month	ion Da			S (I	Price of erivative ecurity nstr. 5)	ive derivative y Securities	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amor or Num of Share	per						

Explanation of Responses:

- 1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.53 to \$2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.40 to \$2.53 inclusive.

/s/ Mark Ballantyne, Attorneyin-Fact 08/28/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.